WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H530714
CAS#: 102577-25-3
Description: Neuromedin N is a peptide from porcine spinal cord with amino acid sequence homologous to COOH-terminal sequence of neurotensin.
Hodoodo Cat#: H530714
Name: Neuromedin N
CAS#: 102577-25-3
Chemical Formula: C38H63N7O8
Exact Mass: 745.47
Molecular Weight: 745.963
Elemental Analysis: C, 61.19; H, 8.51; N, 13.14; O, 17.16
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: Neuromedin N
IUPAC/Chemical Name: Lysyl-isoleucyl-prolyl-tyrosyl-isoleucyl-leucine
InChi Key: RZMLVIHXZGQADB-YLUGYNJDSA-N
InChi Code: InChI=1S/C38H63N7O8/c1-7-23(5)31(36(50)42-29(38(52)53)20-22(3)4)43-34(48)28(21-25-14-16-26(46)17-15-25)41-35(49)30-13-11-19-45(30)37(51)32(24(6)8-2)44-33(47)27(40)12-9-10-18-39/h14-17,22-24,27-32,46H,7-13,18-21,39-40H2,1-6H3,(H,41,49)(H,42,50)(H,43,48)(H,44,47)(H,52,53)/t23-,24-,27-,28-,29-,30-,31-,32-/m0/s1
SMILES Code: CC(C)C[C@@H](C(O)=O)NC([C@H]([C@@H](C)CC)NC([C@H](CC1=CC=C(O)C=C1)NC([C@H]2N(C([C@H]([C@@H](C)CC)NC([C@H](CCCCN)N)=O)=O)CCC2)=O)=O)=O
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >3 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 745.96 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Shults NV, Almansour FS, Rybka V, Suzuki DI, Suzuki YJ. Ligand-mediated dephosphorylation signaling for MAP kinase. Cell Signal. 2018 Dec;52:147-154. doi: 10.1016/j.cellsig.2018.09.005. Epub 2018 Sep 10. PubMed PMID: 30213686.
2: Besserer-Offroy É, Brouillette RL, Lavenus S, Froehlich U, Brumwell A, Murza A, Longpré JM, Marsault É, Grandbois M, Sarret P, Leduc R. The signaling signature of the neurotensin type 1 receptor with endogenous ligands. Eur J Pharmacol. 2017 Jun 15;805:1-13. doi: 10.1016/j.ejphar.2017.03.046. Epub 2017 Mar 22. PubMed PMID: 28341345.
3: Liu Q, Hazan A, Grinman E, Angulo JA. Pharmacological activation of the neurotensin receptor 1 abrogates the methamphetamine-induced striatal apoptosis in the mouse brain. Brain Res. 2017 Mar 15;1659:148-155. doi: 10.1016/j.brainres.2017.01.029. Epub 2017 Jan 25. PubMed PMID: 28130052.
4: Liang YJ, Lin YT, Chen CW, Lin CW, Chao KM, Pan WH, Yang HC. SMART: Statistical Metabolomics Analysis-An R Tool. Anal Chem. 2016 Jun 21;88(12):6334-41. doi: 10.1021/acs.analchem.6b00603. Epub 2016 Jun 1. PubMed PMID: 27248514.
5: Gevaert B, Wynendaele E, Stalmans S, Bracke N, D'Hondt M, Smolders I, van Eeckhaut A, De Spiegeleer B. Blood-brain barrier transport kinetics of the neuromedin peptides NMU, NMN, NMB and NT. Neuropharmacology. 2016 Aug;107:460-470. doi: 10.1016/j.neuropharm.2016.03.051. Epub 2016 Apr 1. PubMed PMID: 27040796.
6: Tóth F, Mallareddy JR, Tourwé D, Lipkowski AW, Bujalska-Zadrozny M, Benyhe S, Ballet S, Tóth G, Kleczkowska P. Synthesis and binding characteristics of [(3)H]neuromedin N, a NTS2 receptor ligand. Neuropeptides. 2016 Jun;57:15-20. doi: 10.1016/j.npep.2015.12.004. Epub 2015 Dec 8. PubMed PMID: 26707235.
7: Maes K, Béchade G, Van Schoors J, Van Wanseele Y, Van Liefferinge J, Michotte Y, Harden SN, Chambers EE, Claereboudt J, Smolders I, Van Eeckhaut A. An ultrasensitive nano UHPLC-ESI-MS/MS method for the quantification of three neuromedin-like peptides in microdialysates. Bioanalysis. 2015;7(5):605-19. doi: 10.4155/bio.14.269. PubMed PMID: 25826142.
8: Ouyang Q, Gong X, Xiao H, Zhou J, Xu M, Dai Y, Xu L, Feng H, Cui H, Yi L. Neurotensin promotes the progression of malignant glioma through NTSR1 and impacts the prognosis of glioma patients. Mol Cancer. 2015 Feb 3;14:21. doi: 10.1186/s12943-015-0290-8. PubMed PMID: 25644759; PubMed Central PMCID: PMC4351837.
9: Maes K, Van Liefferinge J, Viaene J, Van Schoors J, Van Wanseele Y, Béchade G, Chambers EE, Morren H, Michotte Y, Vander Heyden Y, Claereboudt J, Smolders I, Van Eeckhaut A. Improved sensitivity of the nano ultra-high performance liquid chromatography-tandem mass spectrometric analysis of low-concentrated neuropeptides by reducing aspecific adsorption and optimizing the injection solvent. J Chromatogr A. 2014 Sep 19;1360:217-28. doi: 10.1016/j.chroma.2014.07.086. Epub 2014 Aug 1. PubMed PMID: 25145562.
10: Fuxe K, Tarakanov A, Romero Fernandez W, Ferraro L, Tanganelli S, Filip M, Agnati LF, Garriga P, Diaz-Cabiale Z, Borroto-Escuela DO. Diversity and Bias through Receptor-Receptor Interactions in GPCR Heteroreceptor Complexes. Focus on Examples from Dopamine D2 Receptor Heteromerization. Front Endocrinol (Lausanne). 2014 May 13;5:71. doi: 10.3389/fendo.2014.00071. eCollection 2014. Review. PubMed PMID: 24860548; PubMed Central PMCID: PMC4026686.
11: Wakabayashi-Nakao K, Maruyama K, Ishii H, Muramatsu K, Hatakeyama K, Ohshima K, Ogura S, Nakajima T, Yamaguchi K, Mochizuki T. Investigation of proNT/NMN secretion from small cell lung carcinoma cells using a mouse xenograft model. Oncol Rep. 2012 Oct;28(4):1181-6. doi: 10.3892/or.2012.1926. Epub 2012 Jul 23. PubMed PMID: 22825476.
12: Hall FS, Centeno M, Perona MT, Adair J, Dobner PR, Uhl GR. Effects of neurotensin gene knockout in mice on the behavioral effects of cocaine. Psychopharmacology (Berl). 2012 Jan;219(1):35-45. doi: 10.1007/s00213-011-2370-9. Epub 2011 Jul 1. PubMed PMID: 21720755.
13: Wang X, Gulhati P, Li J, Dobner PR, Weiss H, Townsend CM Jr, Evers BM. Characterization of promoter elements regulating the expression of the human neurotensin/neuromedin N gene. J Biol Chem. 2011 Jan 7;286(1):542-54. doi: 10.1074/jbc.M110.145664. Epub 2010 Oct 28. PubMed PMID: 21030593; PubMed Central PMCID: PMC3013014.
14: Kitabgi P. Neurotensin and neuromedin N are differentially processed from a common precursor by prohormone convertases in tissues and cell lines. Results Probl Cell Differ. 2010;50:85-96. doi: 10.1007/400_2009_27. Review. PubMed PMID: 19862492.
15: Ogura S, Kaneko K, Miyajima S, Ohshima K, Yamaguchi K, Mochizuki T. Proneurotensin/neuromedin N secreted from small cell lung carcinoma cell lines as a potential tumor marker. Proteomics Clin Appl. 2008 Dec;2(12):1620-7. doi: 10.1002/prca.200800039. Epub 2008 Nov 14. PubMed PMID: 21136812.
16: Vias M, Burtt G, Culig Z, Veerakumarasivam A, Neal DE, Mills IG. A role for neurotensin in bicalutamide resistant prostate cancer cells. Prostate. 2007 Feb 1;67(2):190-202. PubMed PMID: 17044078.
17: Kitabgi P. Inactivation of neurotensin and neuromedin N by Zn metallopeptidases. Peptides. 2006 Oct;27(10):2515-22. Epub 2006 Aug 9. Review. PubMed PMID: 16904239.
18: Kitabgi P. Differential processing of pro-neurotensin/neuromedin N and relationship to pro-hormone convertases. Peptides. 2006 Oct;27(10):2508-14. Epub 2006 Aug 9. Review. PubMed PMID: 16904237.
19: Kitabgi P. Prohormone convertases differentially process pro-neurotensin/neuromedin N in tissues and cell lines. J Mol Med (Berl). 2006 Aug;84(8):628-34. Epub 2006 May 11. Review. PubMed PMID: 16688434.
20: Kinkead B, Nemeroff CB. Novel treatments of schizophrenia: targeting the neurotensin system. CNS Neurol Disord Drug Targets. 2006 Apr;5(2):205-18. Review. PubMed PMID: 16611093.
